PRSS contributes to cetuximab resistance in colorectal cancer

Cetuximab improves the survival of patients with metastatic colorectal cancer. The main limitation is primary and secondary resistance, the underlying mechanism of which requires extensive investigation. We proved that PRSS expression levels are significantly negatively associated with the sensitivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Zhaoli, Gao, Lihua, Wang, Yan, Yin, Huihui, Xi, Yongyi, Wu, Xiaojie, Shao, Yong, Qiu, Weiyi, Du, Peng, Shen, Wenlong, Fu, Ling, Jia, Ru, Zhao, Chuanhua, Zhang, Yun, Zhao, Zhihu, Sun, Zhiwei, Chen, Hongxing, Hu, Xianwen, Xu, Jianming, Wang, Youliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938705/
https://www.ncbi.nlm.nih.gov/pubmed/31911942
http://dx.doi.org/10.1126/sciadv.aax5576

Ejemplares similares

Ejemplares similares